Seaport Therapeutics reports Q2 2026 results and clinical progress
The company announced full enrollment in its BUOY-1 Phase 2b trial of GlyphAllo for MDD and shared financial highlights, advancing its pipeline of neuropsychiatric therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day